VALANX Biotech

VALANX Biotech and Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development

Joint licensing agreement to commercialize ready-to-conjugate vaccine carrier protein CRM197 will enable rapid development of conjugate vaccines 29 October 2024 -- Klosterneuburg, Austria, and Maryland, US -- VALANX Biotech, a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC, experts in conjugate vaccine development and conjugate...

VALANX Biotech Announces Promising Results in First In-Vivo Study of Novel Protein Conjugate Therapy

Study demonstrates pre-clinical efficacy of lead programme VLX101 in treating autoimmune disease 5 June 2024 - Klosterneuburg, Austria - VALANX Biotech, a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, today announced successful in-vivo results in the company’s lead programme VLX101 for the treatment of a wide range of...
VALANX Biotech Gmbh, Plöcking 1, IST Park Building, 3400 Klosterneuburg, Austria

44(0)7771730919